RT Journal Article
SR Electronic
T1 Prolonged SARS-CoV-2 replication in an immunocompromised patient
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.20.20196899
DO 10.1101/2020.09.20.20196899
A1 Ji Hoon Baang
A1 Christopher Smith
A1 Carmen Mirabelli
A1 Andrew L. Valesano
A1 David M. Manthei
A1 Michael Bachman
A1 Christiane E. Wobus
A1 Michael Adams
A1 Laraine Washer
A1 Emily T. Martin
A1 Adam S. Lauring
YR 2020
UL http://medrxiv.org/content/early/2020/09/22/2020.09.20.20196899.abstract
AB We describe a case of chronic COVID-19 in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious SARS-CoV-2 virus for at least 119 days. The patient had three admissions related to COVID-19 over a four-month period and was treated twice with remdesivir and convalescent plasma with resolution of symptoms. The patient’s lack of seroconversion and prolonged course illustrate the importance of humoral immunity in resolving SARS-CoV-2 infection. This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a COVID-19 Response Innovation Grant from the University of Michigan. Additional support for the enrollment of hospitalized patients with COVID-19 was provided by the CDC (U01 IP000974).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Determined exempt by University of Michigan IRB. Residual clinical specimens were obtained under a protocol approved by the University of Michigan IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available. Links and accession numbers are provided in the manuscript text file.